Arstat Pharmaceuticals is a specialty pharmaceutical company dedicated to solving the most significant unmet needs in women’s healthcare. Led by industry veterans with a track record of billion-dollar successes, 

Arstat is advancing a world-class pipeline of four first-to-market products designed to dominate areas of high unmet medical needs.

𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞:
•𝐍𝐔𝐕𝐎𝐂𝐄𝐏𝐓™: Phase III-ready. The first and only oral contraceptive designed explicitly for women with high BMI (60% of the market).

•𝐃𝐔𝐀𝐂𝐄𝐏𝐓™: Phase III-ready. The first oral contraceptive developed for women with cardiovascular risk factors.

- 𝐏𝐑𝐄𝐌𝐑𝐈𝐍𝐆™: Phase IIb asset. A first-in-category medicated vaginal ring for uterine fibroids and endometriosis, designed to reduce the need for hysterectomies.

- 𝐄𝐍𝐇𝐀𝐍𝐓𝐀™: Phase IIb asset. A first-in-category non-hormonal the
 
The Company's Founder, President, and Chief Scientific Officer, Arkady Rubin, Ph.D., has 35 years of industry experience (J&J, Pfizer). Dr. Rubin is a co-inventor of Ortho Tri-Cyclen Lo, the top-selling oral contraceptive in the U.S. ($1.8B/year in current market conditions)

𝐖𝐡𝐲 𝐀𝐫𝐬𝐭𝐚𝐭?
• 𝐕𝐚𝐥𝐢𝐝𝐚𝐭𝐞𝐝 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞: A combined peak sales potential of $4.7B+
• 𝐀 𝐅𝐨𝐫𝐭𝐫𝐞𝐬𝐬 𝐨𝐟 𝐈𝐏: Protected by 16 granted US and EU patents, with an additional 13 patents planned.
- 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞: Leveraging the abbreviated 505(b)(2) NDA pathway for faster, lower-cost FDA approval.
- 𝐏𝐚𝐭𝐡 𝐭𝐨 𝐋𝐢𝐪𝐮𝐢𝐝𝐢𝐭𝐲: Executing a capital-efficient roadmap toward an IPO in 2026.

We are committed to delivering safe, effective, and innovative therapies that empower women and redefine clinical standards of care.

Please visit the company's website (www.arstatinfo.com) for further details.

𝐀𝐫𝐬𝐭𝐚𝐭 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬, 𝐈𝐧𝐜.

Org chart

Teams

Offices